Results of multivariable regression analysis
| Variable . | Leukemia-free survival . | Relapse . | Nonrelapse mortality . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| RR . | 95% CI . | P . | RR . | 95% CI . | P . | RR . | 95% CI . | P . | |
| Phase of disease* | < .0001 | < .0001 | .006 | ||||||
| CR1 (n = 10) | 0.08 | 0.02-0.29 | 0.01 | 0.00-0.09 | 0.26 | 0.05-1.41 | |||
| CR2 (n = 34) | 0.32 | 0.16-0.67 | 0.13 | 0.04-0.41 | 0.17 | 0.05-0.51 | |||
| CR3 (n = 10) | 0.59 | 0.23-1.54 | 0.61 | 0.12-3.20 | 0.36 | 0.10-1.29 | |||
| Relapse (n = 34) | 1.0 | 1.0 | 1.0 | ||||||
| Age at transplantation | .003 | .48 | < .0001 | ||||||
| 10 y or older (n = 34) | 2.59 | 1.38-4.85 | 0.71 | 0.27-1.86 | 11.7 | 3.86-35.6 | |||
| Younger than 10 y (n = 54) | 1.0 | 1.0 | |||||||
| Duration of CR1† | .005 | .002 | .20 | ||||||
| More than 24 months (n = 47) | 0.41 | 0.23-0.76 | 0.23 | 0.09-0.59 | 0.51 | 0.19-1.40 | |||
| No more 24 months (n = 41) | 1.0 | 1.0 | 1.0 | ||||||
| Phenotype | .005 | .93 | < .0001 | ||||||
| T or null cell (n = 13) | 0.29 | 0.11-0.76 | 1.05 | 0.36-3.08 | 0.0 | NE | |||
| Pre-B cell (n = 75) | 1.0 | 1.0 | 1.0 | ||||||
| Cytogenetic findings | .35 | .03 | .59 | ||||||
| Hyperdiploidy (n = 19) | 1.34 | 0.57-3.13 | 8.49 | 0.95-75.6 | 1.02 | 0.34-3.06 | |||
| Poor risk (n = 14) | 2.55 | 0.83-7.86 | 9.89 | 0.99-98.8 | 3.26 | 0.52-20.5 | |||
| Other abnormal (n = 29) | 2.29 | 0.95-5.51 | 12.7 | 1.52-106 | 0.75 | 0.19-2.92 | |||
| Unknown (n = 9) | 1.23 | 0.39-3.93 | 2.15 | 0.12-39.3 | 0.86 | 0.21-3.56 | |||
| Normal (n = 17) | 1.0 | 1.0 | |||||||
| Year of transplantation | .20 | .02 | .99 | ||||||
| After 1992 (n = 44) | 1.51 | 0.81-2.79 | 3.64 | 1.26-10.5 | 1.00 | 0.41-2.43 | |||
| 1992 or before (n = 44) | 1.0 | 1.0 | 1.0 | ||||||
| Donor-recipient HLA | .25 | .20 | .004 | ||||||
| Mismatch (n = 32) | 1.45 | 0.78-2.72 | 0.52 | 0.18-1.49 | 3.92 | 1.53-10.1 | |||
| Match (n = 56) | 1.0 | 1.0 | 1.0 | ||||||
| Donor-recipient sex | .17 | .58 | .04 | ||||||
| Mismatch (n = 43) | 0.68 | 0.40-1.18 | 0.79 | 0.34-1.82 | 0.39 | 0.15-1.00 | |||
| Match (n = 45) | 1.0 | 1.0 | 1.0 | ||||||
| Variable . | Leukemia-free survival . | Relapse . | Nonrelapse mortality . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| RR . | 95% CI . | P . | RR . | 95% CI . | P . | RR . | 95% CI . | P . | |
| Phase of disease* | < .0001 | < .0001 | .006 | ||||||
| CR1 (n = 10) | 0.08 | 0.02-0.29 | 0.01 | 0.00-0.09 | 0.26 | 0.05-1.41 | |||
| CR2 (n = 34) | 0.32 | 0.16-0.67 | 0.13 | 0.04-0.41 | 0.17 | 0.05-0.51 | |||
| CR3 (n = 10) | 0.59 | 0.23-1.54 | 0.61 | 0.12-3.20 | 0.36 | 0.10-1.29 | |||
| Relapse (n = 34) | 1.0 | 1.0 | 1.0 | ||||||
| Age at transplantation | .003 | .48 | < .0001 | ||||||
| 10 y or older (n = 34) | 2.59 | 1.38-4.85 | 0.71 | 0.27-1.86 | 11.7 | 3.86-35.6 | |||
| Younger than 10 y (n = 54) | 1.0 | 1.0 | |||||||
| Duration of CR1† | .005 | .002 | .20 | ||||||
| More than 24 months (n = 47) | 0.41 | 0.23-0.76 | 0.23 | 0.09-0.59 | 0.51 | 0.19-1.40 | |||
| No more 24 months (n = 41) | 1.0 | 1.0 | 1.0 | ||||||
| Phenotype | .005 | .93 | < .0001 | ||||||
| T or null cell (n = 13) | 0.29 | 0.11-0.76 | 1.05 | 0.36-3.08 | 0.0 | NE | |||
| Pre-B cell (n = 75) | 1.0 | 1.0 | 1.0 | ||||||
| Cytogenetic findings | .35 | .03 | .59 | ||||||
| Hyperdiploidy (n = 19) | 1.34 | 0.57-3.13 | 8.49 | 0.95-75.6 | 1.02 | 0.34-3.06 | |||
| Poor risk (n = 14) | 2.55 | 0.83-7.86 | 9.89 | 0.99-98.8 | 3.26 | 0.52-20.5 | |||
| Other abnormal (n = 29) | 2.29 | 0.95-5.51 | 12.7 | 1.52-106 | 0.75 | 0.19-2.92 | |||
| Unknown (n = 9) | 1.23 | 0.39-3.93 | 2.15 | 0.12-39.3 | 0.86 | 0.21-3.56 | |||
| Normal (n = 17) | 1.0 | 1.0 | |||||||
| Year of transplantation | .20 | .02 | .99 | ||||||
| After 1992 (n = 44) | 1.51 | 0.81-2.79 | 3.64 | 1.26-10.5 | 1.00 | 0.41-2.43 | |||
| 1992 or before (n = 44) | 1.0 | 1.0 | 1.0 | ||||||
| Donor-recipient HLA | .25 | .20 | .004 | ||||||
| Mismatch (n = 32) | 1.45 | 0.78-2.72 | 0.52 | 0.18-1.49 | 3.92 | 1.53-10.1 | |||
| Match (n = 56) | 1.0 | 1.0 | 1.0 | ||||||
| Donor-recipient sex | .17 | .58 | .04 | ||||||
| Mismatch (n = 43) | 0.68 | 0.40-1.18 | 0.79 | 0.34-1.82 | 0.39 | 0.15-1.00 | |||
| Match (n = 45) | 1.0 | 1.0 | 1.0 | ||||||
RR indicates relative risk; CI, confidence interval; CR1, first complete remission; CR2, second complete remission; CR3, third complete remission; and NE, no estimate.
With inclusion of extramedullary relapse in the definition of CR1: EFS, P < .0001; relapse, P < .0001; and NRMP, P = .006.
With inclusion of extramedullary relapse in the definition of CR1: EFS, P = .01; relapse, P = .009; and NRMP, P = .21.